Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have been assigned an average rating of “Buy” from the thirteen brokerages that are covering the company. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $31.92.

ESPR has been the topic of a number of recent research reports. Citigroup Inc set a $39.00 price objective on Esperion Therapeutics and gave the company a “buy” rating in a research report on Monday, March 13th. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. JPMorgan Chase & Co. raised their price objective on Esperion Therapeutics from $22.00 to $50.00 in a research report on Tuesday, March 21st. Needham & Company LLC raised their price objective on Esperion Therapeutics from $25.00 to $58.00 and gave the company a “strong-buy” rating in a research report on Monday, March 20th. Finally, Credit Suisse Group AG raised Esperion Therapeutics from an “underperform” rating to a “neutral” rating and set a $29.00 price objective on the stock in a research report on Monday, March 20th.

In other Esperion Therapeutics news, Director Gilbert S. Omenn purchased 1,000 shares of the stock in a transaction on Tuesday, March 21st. The stock was acquired at an average price of $42.26 per share, with a total value of $42,260.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $422,600. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Dov A. Md Goldstein sold 800,000 shares of the firm’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The disclosure for this sale can be found here. 35.40% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at $205,000. Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares in the last quarter. Finally, American International Group Inc. increased its stake in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 584 shares in the last quarter. 64.65% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Esperion Therapeutics Inc (ESPR) Receives Consensus Rating of “Buy” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/05/22/esperion-therapeutics-inc-espr-receives-consensus-rating-of-buy-from-brokerages.html.

Esperion Therapeutics (NASDAQ:ESPR) traded down 3.03% during trading on Monday, hitting $32.30. The stock had a trading volume of 456,451 shares. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $48.21. The stock’s 50-day moving average is $36.54 and its 200-day moving average is $22.84. The stock’s market capitalization is $729.66 million.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.36. During the same quarter in the prior year, the company earned ($0.65) earnings per share. On average, analysts predict that Esperion Therapeutics will post ($6.69) earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

12 Month Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.